Comparative study of @entity4444 and Mylanta II in the 6-week treatment of XXXX .

@entity1 @entity4444 @entity3775 @entity1760 @entity167 @entity1066 @entity158 @entity2275
The efficacy of antacid in the treatment of benign @entity2275 is less well established than in the treatment of duodenal @entity1066 . The objective of this study was to monitor @entity1066 and symptom relief in 38 @entity1 with gastric ulceration treated for 6 weeks with @entity4444 (Tagamet) 300 mg q.i.d. or an @entity3775 - @entity1760 containing antacid (Mylanta II) 10 ml q.i.d. (acid neutralizing capacity 203.2 mEq/day). The study was single-blind; the study physicians and those providing endoscopic assessments were not aware of the @entity1 ' treatment. Entered into the study were 19 male and 19 female @entity1 ranging in age from 17 to 70 years, with a mean age of 52 years. None of the @entity1 had taken @entity4444 in the previous month, and none abused @entity167 or nonsteroidal anti-inflammatory agents, but two-thirds of the @entity1 were smokers. Five @entity1 in the antacid group withdrew for numerous reasons including continued @entity158 , noncompliance, and side effects. All @entity1 in the @entity4444 group completed the study, and no side effects were noted. There was no difference between the antacid- and the @entity4444 -treated @entity1 in the relief of symptoms. There was a significant difference in the 6-week @entity1066 between the groups, with 14/19 (74%) healed in the @entity4444 group compared with only 6/14 (43%) healed in the antacid group (p less than 0.025). Thus, Mylanta II, 10 ml four times daily, is comparable to @entity4444 300 mg q.i.d. in the symptomatic relief of benign gastric ulceration, but @entity1066 was superior using @entity4444 .
